<DOC>
	<DOC>NCT00563771</DOC>
	<brief_summary>To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia</brief_summary>
	<brief_title>Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Acute hyperuricemia patients before / during chemotherapy for hematologic malignancies ( uric acid greater than 7.5 mg/dL ) With a minimum life expectancy of 3 months Having previously signed a written informed consent. Hypersensitivity to uricase or any of the excipients. Known history of G6PD deficiency. Previous treatment with Rasburicase or Uricozyme. Treatment with any investigational drug within 30 days before planned first Rasburicase administration. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>